All.Can International shared a post on LinkedIn:
“All.Can Belgium brought together a strong and diverse group of stakeholders today to explore what clinically meaningful should truly mean in curative oncology.
A clear message emerged: traditional clinical endpoints remain essential, but they are not sufficient on their own. Survival matters, but so do function, toxicity, long-term wellbeing and patient experience, particularly in curative settings where people live for decades with the consequences of care decisions.
Across patient, clinical, industry, policy and payer perspectives, there was strong alignment that value and innovation can no longer be defined by efficacy alone. Endpoints must better reflect real-world impact and what patients actually live with, shaping trust, adherence and long-term outcomes.
All.Can International was pleased to be present and to support this timely and well-framed discussion. As Pia Cox, AllCan Belgium’s Executive Director, rightly said, the forthcoming white paper should be seen not as an endpoint, but as a starting point for continued multi-stakeholder dialogue on measuring what truly matters in curative oncology!”
More posts featuring All.Can International.
